Cerecor Inc Appoints Dr. Sol Barer Chairman of the Board
(firmenpresse) - BALTIMORE, MD -- (Marketwire) -- 01/10/12 -- Cerecor Inc today announced that Sol J. Barer, Ph.D., a current board member, has been elected the Chairman of Cerecor's Board of Directors, effective immediately. Cerecor thanks Eugene Bauer, MD for his contributions as chairman, leading the Company to its current successful stage. Dr. Bauer will continue as a member of the Board of Directors.
"I am delighted that Dr. Barer has agreed to become chairman of Cerecor and I am confident that with his guidance we are positioned to achieve significant value creation as we develop therapies for diseases that have important unmet medical needs," said Blake Paterson, M.D., co-founder and CEO of Cerecor. Dr. Barer commented, "I am very pleased to have been asked to take the Chairman's role and I look forward to working with the Board and management in developing products and positioning the Company for enhanced shareholder value."
Dr. Barer has more than 30 years experience with publicly traded biotechnology companies. In 1980, he was with Celanese Research Company when he formed the biotechnology group that was subsequently spun out to form Celgene. Dr. Barer spent 18 years leading Celgene, holding the positions of president, COO and Chairman and CEO during different periods, culminating with his tenure as Celgene's Executive Chairman before retiring in June of 2011. Dr. Barer serves on the Board of several companies including: Amicus Therapeutics, Inc., Aegerion Pharmaceuticals, Inc., ContraFect Corp., Edge Therapeutics, Inc., and is Chairman of the Board of InspireMD, Inc. He serves as Chairman of BioNJ Inc., the 300 company biotechnology organization of New Jersey, as Chairman of the Governor of New Jersey's UMDNJ Advisory Committee and advises several corporations.
About Cerecor: Cerecor is a Maryland-based biopharmaceutical company focused on the discovery, development and commercialization of prescription pharmaceuticals whose primary site of activity is in the human brain. We are focused on translational medicine -- the accelerated transfer of discoveries from the academic laboratory to human studies of potential drugs, with the goal of rapid commercialization. Our current product opportunities are in cough, schizophrenia and cognition, originated from various laboratories and research institutes at the Johns Hopkins Medical Institutes.
Cerecor
410-522-8707
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 10.01.2012 - 12:36 Uhr
Sprache: Deutsch
News-ID 1071689
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
BALTIMORE, MD
Phone:
Kategorie:
Biotech
Anmerkungen:
Diese Pressemitteilung wurde bisher 115 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Cerecor Inc Appoints Dr. Sol Barer Chairman of the Board
"
steht unter der journalistisch-redaktionellen Verantwortung von
Cerecor Inc (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
